Orifarm

Andreas Søderman

In the ever-evolving landscape of pharmaceuticals, the role of Medical Affairs is often associated with the cutting-edge innovations that bring blockbuster drugs to the market. However, there's untapped potential in applying the same rigor and expertise in the world of generics, value-added medicines, and hybrid pharmaceuticals.

What's more, the generic world itself is undergoing a seismic shift. Many companies are moving away from the pure generics game, steering towards value-added medicines and complex, difficult-to-make formulations. Medical Affairs plays a crucial role here, not just as a gatekeeper for quality and documented communication but as a visionary force defining the future portfolios of these companies. By identifying unmet medical needs, we have the opportunity to guide incremental improvements that can significantly impact patient outcomes.

Medical Affairs acts as the glue, connecting the scientific underpinnings with the commercial reality. This involves more than just ensuring bioequivalence or tapping into cost-effectiveness; it’s about enhancing value in a way that directly impacts patient care.

Remember the days when aspirin was just aspirin? Now, we have formulations that are easier on the stomach, quicker to act, and more convenient to take. This didn't happen by magic; it was a concerted effort of formulators, clinicians, and yes, Medical Affairs professionals who understood both the scientific and marketplace needs.

Data analytics and real-world evidence have also become indispensable tools in our arsenal. While we're not building drugs from the ground up, we're upgrading them, fortifying them with new value. Take, for instance, the generic antihypertensive medication now equipped with a built-in adherence monitor. This is a game-changer in managing conditions that demand consistent medication, thereby potentially improving health outcomes.

The key is adaptability. The ability to adapt and refine existing medications allows us to respond quickly to emerging patient needs, healthcare trends, and even global pandemics.

Realizing this potential isn’t a solo endeavor. It requires multi-disciplinary teams working in unison, decisions backed by robust data, and most importantly, a vision that looks beyond profits. It's not just what you bring to the market; it's what you bring to the patient that counts.

As generic companies evolve from focusing solely on generics to incorporating more value-added medicines, Medical Affairs—still a relatively new function in the generics landscape will become a crucial cornerstone for future success.